杭州浙大迪迅生物基因工程有限公司Release date：2020-09-04
Allergy
[IF:6.771]
Artemisia annua-sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial
DOI: 10.1111/all.14218
Abstract:
Background: Artemisia annua is an important autumnal pollen allergen for seasonal allergic rhinitis (SAR) in northern China. To date, no study has investigated allergen immunotherapy with A annua. We aimed to investigate the efficacy and mechanisms underlying A annua-sublingual immunotherapy (SLIT).
Methods: This was a randomized, double-blind, placebo-controlled phase III clinical trial involving 71 SAR patients, randomized to SLIT with A annua extract (n = 47) or placebo (n = 24) for 32 weeks. Total nasal symptom score (TNSS; primary clinical end point) was evaluated at baseline (peak pollen phase (PPP) in the previous year), initiation of A annua-SLIT, 1st PPP during SLIT, end of SLIT and 2nd PPP during follow-up. Blood samples and nasal secretions were collected at beginning and after SLIT for assessment of T cells and inflammatory mediators. Safety was assessed according to adverse events (AEs) reported.
Results: Artemisia annua-SLIT significantly reduced TNSS to a greater level from baseline (from 9.45 ± 1.68 to 6.16 ± 2.27) than placebo (from 9.29 ± 2.09 to 9.05 ± 2.40) at the 1st PPP (P < .001) and sustained the improvement in symptoms throughout to the 2nd PPP. Preseasonal A annua-SLIT for 16 weeks significantly decreased Th2 cells, increased nTreg and Tr1 cells in blood; and increased cystatin 1 (CST1) in nasal secretion after 16 and 32 weeks compared with pretreatment. Overall, 17/47 patients experienced mild local AEs and 2 patients mild systemic AEs, after A annua-SLIT.
Conclusion: Artemisia annua-SLIT is an efficacious and safe treatment in patients with A annua SAR.
First Author:
Hongfei Lou, Chengshuo Wang
Correspondence:
Chengshuo Wang, Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, No.1, Dongjiaominxiang, DongCheng District, Beijing 100730, China.
All Authors:
Hongfei Lou, Yanran Huang,Yuhui Ouyang,Yuan Zhang, Lin Xi, Xiaohan Chu, Yang Wang, Chengshuo Wang, Luo Zhang
2020-08-19 Article
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd. Copyright HZKC Technical support 浙ICP備14005341號 （浙）-非經(jīng)營性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist. Tel: 0571-87968248-805 Website:www.haosf.js.cn
COPYRIGHT©2003-2024 www.haosf.js.cn CORPORATION. ALL RIGHTS RESERVED
Official WeChat